Deteksi dan Penanganan Awal Miokarditis dan Miokarditis Fulminan

  • Siti Elkana Nauli Department of Cardiology and Vascular Medicine, Tangerang District Hospital
  • Hawani Sasmaya Prameswari Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Pajajaran, Hasan Sadikin Hospital Bandung
Keywords: indonesia


Myocarditis is commonly caused due to systemic viral infection with cardiotropic nature. In the acute phase, this disorder could cause lethal hemodynamic or arrhythmic disorders. Newest studies showed that the use of guideline-directed medical care in the care of myocarditis will lead to better outcomes. This condition varies in presentation ranging from mild to life-threatening such as cardiogenic shock. With the current advances in early detection and circulatory support using extracorporeal membrane oxygenation (ECMO), myocarditis could be managed very well. Cases of myocarditis related to COVID 19 has been reported, however as per this time there has no confirmed pathological evidence regarding direct causation between COVID19 and myocarditis, however, in these severely ill patients, elevations in cardiac biomarkers (cTn, BNP and NTproBNP) occurs, and the administration of immunosuppressant could increase the chance of remission.

Keyword: Myocarditis, fulminant, COVID 19.


Download data is not yet available.


1. Tschöpe C, Cooper LT, Amione GT, Linthout SV. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res. 2019; 124: 1568-1583.
2. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pand PS, Sabe MA, et al. Recognition and Initial Management of Fulminant Myocarditis. Circulation. 2020; 141:1-24.
3. Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL, Hare JM. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36:227–232.
4. Pinto JM, Schumm LP, Wroblewski KE, Kern DW, McClintock MK. Racial disparities in olfactory loss among older adults in the Unit- ed States. J Gerontol A Biol Sci Med Sci. 2014;69:323–329.
5. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, et al; European Society of Cardiol- ogy Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiol- ogy Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48, 2648a.
6. Skouri HN, Dec GW, Friedrich MG, Cooper LT. Noninvasive imag- ing in myocarditis. J Am Coll Cardiol. 2006;48:2085–2093.
7. Hiramitsu S, Morimoto S, Kato S, Uemura A, Ohtsuki M, Kato Y, Sugiura A, Miyagishima K, Mori N, Yoda R, et al. Significance of transient left ven- tricular wall thickening in acute lymphocytic myocarditis. Heart Vessels. 2007;22:25–29.
8. Shillcutt SK, Thomas WR, Sullivan JN, Duhachek-Stapelman A. Fulminant myocarditis: the role of perioperative echocardiography. Anesth Analg. 2015;120:296–299.
9. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, Petrella D, Garascia A, Pedrotti P, Roghi A, et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation. 2017;136:529–545.
10. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52:274– 288.
11. Escher F, Kasner M, Kühl U, Heymer J, Wilkenshoff U, Tschöpe C, Schultheiss HP. New echocardiographic findings correlate with intramyo- cardial inflammation in endomyocardial biopsies of patients with acute myocarditis and inflammatory cardiomyopathy. Mediators Inflamm. 2013;2013:875420.
12. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, et al; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475–1487.
13. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, et al. Cardio- vascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158–3176.
14. Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, Fuernau G, de Waha S, Sareban M, Luecke C, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging. 2012;5:513–524.
15. Sujino Y, Kimura F, Tanno J, Nakano S, Yamaguchi E, Shimizu M, Okano N, Tamura Y, Fujita J, Cooper LT, et al. Cardiac magnetic reso- nance imaging in giant cell myocarditis: intriguing associations with clinical and pathological features. Circulation. 2014;129:e467–e469.
16. Kim EY, Chang SA, Lee YK, Choi JO, Choe YH. Early non-invasive di- agnosis and treatment of acute eosinophilic myopericarditis by car- diac magnetic resonance. J Korean Med Sci. 2011;26:1522–1526. doi: 10.3346/jkms.2011.26.11.1522.
17. Tani H, Amano Y, Tachi M, Machida T, Mizuno K, Kumita S. T2-weight- ed and delayed enhancement MRI of eosinophilic myocarditis: rela- tionship with clinical phases and global cardiac function. Jpn J Radiol. 2012;30:824–831. doi: 10.1007/s11604-012-0130-3.
18. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–2233.
19. Pankuweit S, Maisch B. Etiology, diagnosis, management, and treatment of myocarditis: position paper from the ESC Working Group on Myocar- dial and Pericardial Diseases [in German]. Herz. 2013;38:855–861.
20. Jeserich M, Konstantinides S, Pavlik G, Bode C, Geibel A. Non-invasive imaging in the diagnosis of acute viral myocarditis. Clin Res Cardiol. 2009;98:753–763.
21. Dec GW, Palacios I, Yasuda T, Fallon JT, Khaw BA, Strauss HW, Haber E. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol. 1990;16:97–104.
22. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M, Kobayashi Y. Determination of optimum periods between onset of sus- pected acute myocarditis and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. Int J Cardiol. 2013;169:196–200.
23. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A, Herfkens R. Initial experience with simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis. Clin Nucl Med. 2017;42:e328–e334.
24. Berg J, Kottwitz J, Baltensperger N, Kissel CK, Lovrinovic M, Mehra T, Scherff F, Schmied C, Templin C, Luscher TF, et al. Cardiac mag- netic resonance imaging in myocarditis reveals persistent disease activ- ity despite normalization of cardiac enzymes and inflammatory param- eters at 3-month follow-up. Circ Heart Fail. 2017;10:e004262.
25. Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, Halushka MK, Russell SD. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. Circ Heart Fail. 2013;6:676–684.
26. Heidecker B, Kittleson MM, Kasper EK, Wittstein IS, Champion HC, Russell SD, Hruban RH, Rodriguez ER, Baughman KL, Hare JM. Transcrip- tomic biomarkers for the accurate diagnosis of myocarditis. Circulation. 2011;123:1174–1184.
27. Peretto G, Sala S, Rizzo S, De Luca G, Campochiaro C, Sartorelli S, Benedetti G, Palmisano A, Esposito A, Tresoldi M, et al. Arrhythmias in myo- carditis: state of the art. Heart Rhythm. 2019;16:793–801.
28. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, Mantovani R, Varrenti M, Pedrotti P, Conca C, et al; on behalf of the Registro Lombardo delle Miocarditi. Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis. Circulation. 2018;138:1088– 1099.
29. Sanguineti F, Garot P, Mana M, O’h-Ici D, Hovasse T, Unterseeh T, Louvard Y, Troussier X, Morice MC, Garot J. Cardiovascular magnetic resonance pre- dictors of clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2015;17:78.
30. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, et al; on behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–e268.
31. Cooper LT Jr, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, Menon S, Mullen GM, Jaski B, Bailey KR, et al. Usefulness of immunosup- pression for giant cell myocarditis. Am J Cardiol. 2008;102:1535–1539.
32. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocardi- tis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–695.
33. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526–1538. doi: 10.1056/NEJMra0800028
34. Fung G, Luo H, Qiu Y, Yang D, McManus B. Myocarditis. Circ Res. 2016;118:496–514.
35. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803–818.
36. Global Burden of Disease Study Collaborators. Global, regional, and na- tional incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a sys- tematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.
37. Engler RJ, Nelson MR, Collins LC Jr, Spooner C, Hemann BA, Gibbs BT, Atwood JE, Howard RS, Chang AS, Cruser DL, et al. A prospec- tive study of the incidence of myocarditis/pericarditis and new onset car- diac symptoms following smallpox and influenza vaccination. PLoS One. 2015;10:e0118283.
38. CaseyCG,IskanderJK,RoperMH,MastEE,WenXJ,TörökTJ,ChapmanLE, Swerdlow DL, Morgan J, Heffelfinger JD, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA. 2005;294:2734–2743.
39. Atluri P, Ullery BW, MacArthur JW, Goldstone AB, Fairman AS, Hiesinger W, Acker MA, Woo YJ. Rapid onset of fulminant myocarditis portends a favourable prognosis and the ability to bridge mechanical cir- culatory support to recovery. Eur J Cardiothorac Surg. 2013;43:379–382.
40. Boehmer JP, Starling RC, Cooper LT, Torre-Amione G, Wittstein I, Dec GW, Markham DW, Zucker MJ, Gorcsan J 3rd, McTiernan C, et al; IMAC Investigators. Left ventricular assist device support and myocardial recovery in recent onset cardiomyopathy. J Card Fail. 2012;18:755–761. doi: 10.1016/j.cardfail.2012.08.001.
41. Alhazzani W, Hylander Møller M, Arabi YM, Loeb M, Ng Gong M, Fan E. Surviving Sepsis Campaign : Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (Covid 19). Canadian Cardiovascular Society, 22 March 2020.
42. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Diasease. Circulation.2020: 1-19.
43. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felox AB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Hear J.2013:2636-48.
44. Tschöpe C, Cooper LT, Amione GT, Linthout SV. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res. 2019; 124: 1568-1583.
45. KühlU,PauschingerM,SchwimmbeckPL,SeebergB,LoberC,NoutsiasM, Poller W, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793–2798.
46. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, et al. Betaferon in Chronic Viral Cardiomyopathy (BICC) trial: effects of interferon-β treat- ment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016;105:763–773.
47. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis: the Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–275.
48. Davies RA, Veinot JP, Smith S, Struthers C, Hendry P, Masters R. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant. 2002;21:674–679.
49. Scott RL, Ratliff NB, Starling RC, Young JB. Recurrence of giant cell myo- carditis in cardiac allograft. J Heart Lung Transplant. 2001;20:375–380.
50. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15–22.
51. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, Bailey KR, Cooper LT. A clinical and histopathologic comparison of car- diac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41:322–329.
52. Larsen BT, Maleszewski JJ, Edwards WD, Cooper LT Jr, Sobonya RE, Thompson VE, Duckett SG, Peebles CR, Simpson IA, Tazelaar HD. Atrial giant cell myocarditis: a distinctive clinicopathologic entity. Circulation. 2013;127:39–47.
53. Evans JD, Pettit SJ, Goddard M, Lewis C, Parameshwar JK. Alemtu- zumab as a novel treatment for refractory giant cell myocarditis after heart transplantation. J Heart Lung Transplant. 2016;35:256–258.
54. Elamm CA, Al-Kindi SG, Bianco CM, Dhakal BP, Oliveira GH. Heart transplantation in giant cell myocarditis: analysis of the United Net- work for Organ Sharing Registry. J Card Fail. 2017;23:566–569.
55. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343:1388– 1398.
56. Grabmaier U, Brenner C, Methe H, Kaczmarek I, Schramm R, Klingel K, Hagl C, Franz WM. An alternative immunosuppressive regimen to pro- long transplant free survival in a patient with giant cell myocarditis. Int J Cardiol. 2013;168:e27–e28.
57. Kontani M, Takashima S, Okura K, Takemori H, Maeno K, Tanaka N, Ohashi H, Noriki S. Survival after acute necrotizing eosinophilic myocardi- tis complicating a massive left ventricular mural thrombus: a case report. J Cardiol. 2007;50:127–133.
58. Cooper LT, Zehr KJ. Biventricular assist device placement and immuno- suppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med. 2005;2:544–548.
59. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70:2363–2375.
60. Allen SF, Godley RW, Evron JM, Heider A, Nicklas JM, Thomas MP. Acute necrotizing eosinophilic myocarditis in a patient taking Garcinia cambogia extract successfully treated with high-dose corticosteroids. Can J Cardiol. 2014;30:1732.e13–1732.e15.
61. Bleeker JS, Syed FF, Cooper LT, Weiler CR, Tefferi A, Pardanani A. Treat- ment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs. Am J Hematol. 2012;87:703–706.
62. Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, et al. Trial watch: im- mune checkpoint blockers for cancer therapy. Oncoimmunology. 2017;6:e1373237.
63. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
64. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myo- carditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
65. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.
66. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y. Immune checkpoint inhibitor-associated myositis. Circulation. 2018;138:743– 745.
67. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep.2017;19:21.
68. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al; National Comprehen- sive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Ameri- can Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–1768.
69. Hu J-R, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854–868.
70. Alhazzani W, Hylander Møller M,Arabi YM, Loeb M, Ng Gong M, Fan E. Surviving Sepsis Campaign : Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (Covid 19). Canadian Cardiovascular Society, 22 March 2020.
Views & Downloads
Abstract views: 4931   
PDF downloads: 9741   
How to Cite
Nauli, S., & Prameswari, H. (2020). Deteksi dan Penanganan Awal Miokarditis dan Miokarditis Fulminan. Indonesian Journal of Cardiology, 41(2), 71-82.